Global Glucagon-like Peptide-1 Receptor Agonist Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 280946
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Glucagon-like Peptide-1 Receptor Agonist market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Glucagon-like Peptide-1 Receptor Agonist market size is estimated to be worth US$ 9071.4 million in 2021 and is forecast to a readjusted size of USD 20650 million by 2028 with a CAGR of 12.5% during review period. Solid Tumors accounting for % of the Glucagon-like Peptide-1 Receptor Agonist global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Exenatide segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Glucagon-like Peptide-1 Receptor Agonist include GSK, Novo Nordisk, Lily, Haosoh, and Sanofi, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Glucagon-like Peptide-1 Receptor Agonist market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Exenatide

Liraglutide

Lixisenatide

Albiglutide

Others

Market segment by Application, can be divided into

Solid Tumors

Blood-related Tumors

Market segment by players, this report covers

GSK

Novo Nordisk

Lily

Haosoh

Sanofi

AstraZeneca

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Glucagon-like Peptide-1 Receptor Agonist product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Glucagon-like Peptide-1 Receptor Agonist, with revenue, gross margin and global market share of Glucagon-like Peptide-1 Receptor Agonist from 2019 to 2022.

Chapter 3, the Glucagon-like Peptide-1 Receptor Agonist competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Glucagon-like Peptide-1 Receptor Agonist market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Glucagon-like Peptide-1 Receptor Agonist research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1 Market Overview

1.1 Product Overview and Scope of Glucagon-like Peptide-1 Receptor Agonist

1.2 Classification of Glucagon-like Peptide-1 Receptor Agonist by Type

1.2.1 Overview: Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Type in 2021

1.2.3 Exenatide

1.2.4 Liraglutide

1.2.5 Lixisenatide

1.2.6 Albiglutide

1.2.7 Others

1.3 Global Glucagon-like Peptide-1 Receptor Agonist Market by Application

1.3.1 Overview: Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Solid Tumors

1.3.3 Blood-related Tumors

1.4 Global Glucagon-like Peptide-1 Receptor Agonist Market Size & Forecast

1.5 Global Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast by Region

1.5.1 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Size by Region, (2017-2022)

1.5.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2017-2028)

1.5.4 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2017-2028)

1.5.6 South America Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Glucagon-like Peptide-1 Receptor Agonist Market Drivers

1.6.2 Glucagon-like Peptide-1 Receptor Agonist Market Restraints

1.6.3 Glucagon-like Peptide-1 Receptor Agonist Trends Analysis

2 Company Profiles

2 Company Profiles

2.1 GSK

2.1.1 GSK Details

2.1.2 GSK Major Business

2.1.3 GSK Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

2.1.4 GSK Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 GSK Recent Developments and Future Plans

2.2 Novo Nordisk

2.2.1 Novo Nordisk Details

2.2.2 Novo Nordisk Major Business

2.2.3 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

2.2.4 Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Novo Nordisk Recent Developments and Future Plans

2.3 Lily

2.3.1 Lily Details

2.3.2 Lily Major Business

2.3.3 Lily Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

2.3.4 Lily Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Lily Recent Developments and Future Plans

2.4 Haosoh

2.4.1 Haosoh Details

2.4.2 Haosoh Major Business

2.4.3 Haosoh Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

2.4.4 Haosoh Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Haosoh Recent Developments and Future Plans

2.5 Sanofi

2.5.1 Sanofi Details

2.5.2 Sanofi Major Business

2.5.3 Sanofi Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

2.5.4 Sanofi Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Sanofi Recent Developments and Future Plans

2.6 AstraZeneca

2.6.1 AstraZeneca Details

2.6.2 AstraZeneca Major Business

2.6.3 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

2.6.4 AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 AstraZeneca Recent Developments and Future Plans

3 Market Competition, by Players

3 Market Competition, by Players

3.1 Global Glucagon-like Peptide-1 Receptor Agonist Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Glucagon-like Peptide-1 Receptor Agonist Players Market Share in 2021

3.2.2 Top 10 Glucagon-like Peptide-1 Receptor Agonist Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Glucagon-like Peptide-1 Receptor Agonist Players Head Office, Products and Services Provided

3.4 Glucagon-like Peptide-1 Receptor Agonist Mergers & Acquisitions

3.5 Glucagon-like Peptide-1 Receptor Agonist New Entrants and Expansion Plans

4 Market Size Segment by Type

4 Market Size Segment by Type

4.1 Global Glucagon-like Peptide-1 Receptor Agonist Revenue and Market Share by Type (2017-2022)

4.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5 Market Size Segment by Application

5.1 Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Application (2017-2022)

5.2 Global Glucagon-like Peptide-1 Receptor Agonist Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6 North America by Country, by Type, and by Application

6.1 North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2028)

6.2 North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2028)

6.3 North America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country

6.3.1 North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2028)

6.3.2 United States Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

6.3.3 Canada Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

6.3.4 Mexico Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7 Europe by Country, by Type, and by Application

7.1 Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2028)

7.2 Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2028)

7.3 Europe Glucagon-like Peptide-1 Receptor Agonist Market Size by Country

7.3.1 Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2028)

7.3.2 Germany Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

7.3.3 France Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

7.3.5 Russia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

7.3.6 Italy Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2028)

8.2 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2028)

8.3 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Market Size by Region

8.3.1 Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Region (2017-2028)

8.3.2 China Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

8.3.3 Japan Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

8.3.4 South Korea Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

8.3.5 India Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

8.3.7 Australia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9 South America by Country, by Type, and by Application

9.1 South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2028)

9.2 South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2028)

9.3 South America Glucagon-like Peptide-1 Receptor Agonist Market Size by Country

9.3.1 South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2028)

9.3.2 Brazil Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

9.3.3 Argentina Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2028)

10.2 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2028)

10.3 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Market Size by Country

10.3.1 Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2028)

10.3.2 Turkey Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

10.3.4 UAE Glucagon-like Peptide-1 Receptor Agonist Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

11 Research Findings and Conclusion

12 Appendix

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Glucagon-like Peptide-1 Receptor Agonist Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Glucagon-like Peptide-1 Receptor Agonist Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Glucagon-like Peptide-1 Receptor Agonist Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) by Region (2017-2022)

Table 5. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Region (2023-2028)

Table 6. GSK Corporate Information, Head Office, and Major Competitors

Table 7. GSK Major Business

Table 8. GSK Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

Table 9. GSK Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Novo Nordisk Corporate Information, Head Office, and Major Competitors

Table 11. Novo Nordisk Major Business

Table 12. Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

Table 13. Novo Nordisk Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Lily Corporate Information, Head Office, and Major Competitors

Table 15. Lily Major Business

Table 16. Lily Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

Table 17. Lily Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Haosoh Corporate Information, Head Office, and Major Competitors

Table 19. Haosoh Major Business

Table 20. Haosoh Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

Table 21. Haosoh Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Sanofi Corporate Information, Head Office, and Major Competitors

Table 23. Sanofi Major Business

Table 24. Sanofi Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

Table 25. Sanofi Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 27. AstraZeneca Major Business

Table 28. AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Product and Solutions

Table 29. AstraZeneca Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Global Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 31. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 32. Breakdown of Glucagon-like Peptide-1 Receptor Agonist by Company Type (Tier 1, Tier 2 and Tier 3)

Table 33. Glucagon-like Peptide-1 Receptor Agonist Players Head Office, Products and Services Provided

Table 34. Glucagon-like Peptide-1 Receptor Agonist Mergers & Acquisitions in the Past Five Years

Table 35. Glucagon-like Peptide-1 Receptor Agonist New Entrants and Expansion Plans

Table 36. Global Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) by Type (2017-2022)

Table 37. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Type (2017-2022)

Table 38. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Forecast by Type (2023-2028)

Table 39. Global Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2022)

Table 40. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Forecast by Application (2023-2028)

Table 41. North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2022) & (USD Million)

Table 42. North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2023-2028) & (USD Million)

Table 43. North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2022) & (USD Million)

Table 44. North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2023-2028) & (USD Million)

Table 45. North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2022) & (USD Million)

Table 46. North America Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2023-2028) & (USD Million)

Table 47. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2022) & (USD Million)

Table 48. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2023-2028) & (USD Million)

Table 49. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2022) & (USD Million)

Table 50. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2023-2028) & (USD Million)

Table 51. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2022) & (USD Million)

Table 52. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2023-2028) & (USD Million)

Table 53. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2022) & (USD Million)

Table 54. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2023-2028) & (USD Million)

Table 55. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2022) & (USD Million)

Table 56. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2023-2028) & (USD Million)

Table 57. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Region (2017-2022) & (USD Million)

Table 58. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue by Region (2023-2028) & (USD Million)

Table 59. South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2022) & (USD Million)

Table 60. South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2023-2028) & (USD Million)

Table 61. South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2022) & (USD Million)

Table 62. South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2023-2028) & (USD Million)

Table 63. South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2022) & (USD Million)

Table 64. South America Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2023-2028) & (USD Million)

Table 65. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2017-2022) & (USD Million)

Table 66. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Type (2023-2028) & (USD Million)

Table 67. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2017-2022) & (USD Million)

Table 68. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Application (2023-2028) & (USD Million)

Table 69. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2017-2022) & (USD Million)

Table 70. Middle East & Africa Glucagon-like Peptide-1 Receptor Agonist Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Glucagon-like Peptide-1 Receptor Agonist Picture

Figure 2. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Type in 2021

Figure 3. Exenatide

Figure 4. Liraglutide

Figure 5. Lixisenatide

Figure 6. Albiglutide

Figure 7. Others

Figure 8. Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Application in 2021

Figure 9. Solid Tumors Picture

Figure 10. Blood-related Tumors Picture

Figure 11. Global Glucagon-like Peptide-1 Receptor Agonist Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 12. Global Glucagon-like Peptide-1 Receptor Agonist Revenue and Forecast (2017-2028) & (USD Million)

Figure 13. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Region (2017-2028)

Figure 14. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Region in 2021

Figure 15. North America Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) and Growth Rate (2017-2028)

Figure 16. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. South America Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Glucagon-like Peptide-1 Receptor Agonist Market Drivers

Figure 21. Glucagon-like Peptide-1 Receptor Agonist Market Restraints

Figure 22. Glucagon-like Peptide-1 Receptor Agonist Market Trends

Figure 23. GSK Recent Developments and Future Plans

Figure 24. Novo Nordisk Recent Developments and Future Plans

Figure 25. Lily Recent Developments and Future Plans

Figure 26. Haosoh Recent Developments and Future Plans

Figure 27. Sanofi Recent Developments and Future Plans

Figure 28. AstraZeneca Recent Developments and Future Plans

Figure 29. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Players in 2021

Figure 30. Glucagon-like Peptide-1 Receptor Agonist Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 31. Global Top 3 Players Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share in 2021

Figure 32. Global Top 10 Players Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share in 2021

Figure 33. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 34. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Type in 2021

Figure 35. Global Glucagon-like Peptide-1 Receptor Agonist Market Share Forecast by Type (2023-2028)

Figure 36. Global Glucagon-like Peptide-1 Receptor Agonist Revenue Share by Application in 2021

Figure 37. Global Glucagon-like Peptide-1 Receptor Agonist Market Share Forecast by Application (2023-2028)

Figure 38. North America Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Type (2017-2028)

Figure 39. North America Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Application (2017-2028)

Figure 40. North America Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Country (2017-2028)

Figure 41. United States Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 42. Canada Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 43. Mexico Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 44. Europe Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Type (2017-2028)

Figure 45. Europe Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Application (2017-2028)

Figure 46. Europe Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Country (2017-2028)

Figure 47. Germany Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 48. France Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 49. United Kingdom Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 50. Russia Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 51. Italy Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Type (2017-2028)

Figure 53. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Application (2017-2028)

Figure 54. Asia-Pacific Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Region (2017-2028)

Figure 55. China Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 56. Japan Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 57. South Korea Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. India Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. Southeast Asia Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Australia Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. South America Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Type (2017-2028)

Figure 62. South America Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Application (2017-2028)

Figure 63. South America Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Country (2017-2028)

Figure 64. Brazil Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 65. Argentina Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Type (2017-2028)

Figure 67. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Sales Market Share by Application (2017-2028)

Figure 68. Middle East and Africa Glucagon-like Peptide-1 Receptor Agonist Revenue Market Share by Country (2017-2028)

Figure 69. Turkey Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Saudi Arabia Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. UAE Glucagon-like Peptide-1 Receptor Agonist Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 72. Methodology

Figure 73. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz